| Name | Title | Contact Details |
|---|---|---|
Rocky Rankin |
Vice President of Technology | Profile |
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
ATTILA TECHNOLOGIES is a Hoboken, NJ-based company in the Software and Internet sector.
FunMobility provides marketing solutions for a mobile-first world. We create campaigns powered by HTML5 Nanosites -- lightweight & interactive content elements -- that link together to deliver fun and engaging experiences across all marketing touch poi...
Memfault is an IoT reliability platform that empowers teams to build more robust devices at scale through performance monitoring, debugging, and OTA updates. Their SDK and web app enable device reliability engineering (DRE) techniques, providing a more...
CyFlare is a leading Open XDR Enabled SOCaaS Provider rated as a Top 100 MSSP for 4 years running. They specialize in SOCaaS, security automation, incident response playbooks, and interactive analytics built for the boardroom, all in a single appliance...